Lilly(US:LLY) GLP1减重宝典·2025-12-07 03:02Core Insights - The article discusses the efficacy and safety of Tirzepatide for weight reduction in Chinese adults with obesity, based on a clinical trial published in JAMA [2][3]. Group 1: Clinical Trial Results - The SURMOUNT-CN trial demonstrated that participants receiving a 15 mg dose of Tirzepatide lost an average of 17.5% of their body weight (16.1 kg) after 52 weeks [3]. - The trial involved 29 centers in China and included adults with a BMI of 28 or higher, or 24 or higher with at least one weight-related comorbidity [3]. - Weight loss percentages at week 52 for the 10 mg, 15 mg, and placebo groups were 13.6%, 17.5%, and 2.3%, respectively [4]. Group 2: Safety and Side Effects - The most common adverse events during Tirzepatide treatment were gastrointestinal issues, mostly mild to moderate in severity, with less than 5% of patients discontinuing treatment due to side effects [4]. - The trial concluded that weekly doses of 10 mg or 15 mg of Tirzepatide provide statistically and clinically significant weight loss with acceptable safety [4]. Group 3: Market Performance and Sales - Eli Lilly reported Q3 2025 revenue of $17.601 billion, a 54% increase year-over-year, with total revenue for the first nine months of 2025 reaching $45.887 billion (+46%) [5]. - Tirzepatide (Mounjaro and Zepbound) significantly contributed to Eli Lilly's revenue, generating $24.837 billion (+125%) in the first three quarters of 2025 [5][6]. - In the U.S. market, Eli Lilly's GLP-1 market share has surpassed that of Novo Nordisk, with prescription volume shares of 57.9% vs 41.7% as of Q3 [7].